RxDoctor Payments Data

Stephen Lambert, MD

Family Medicine · Hattiesburg, MSNPI 1851395479

Payments from drug & device makers

$8,821in general payments, 2019–2025

Across 647 payments — averaging $13.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AstraZeneca$1K
  • Amgen$778
  • Novo Nordisk$589
  • Boehringer Ingelheim$554
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,815100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,821 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$221,421
Medicare patients
540
Services billed
7,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide86$108,546
JardianceEmpagliflozin91$104,735
OzempicSemaglutide68$85,321
FarxigaDapagliflozin Propanediol91$66,859
EliquisApixaban74$61,798
JanuviaSitagliptin Phosphate59$52,666
LinzessLinaclotide62$44,250
RybelsusSemaglutide31$40,018
XareltoRivaroxaban42$36,097
EntrestoSacubitril/Valsartan27$25,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,836
InvokanaCanagliflozin12$20,578
BrilintaTicagrelor23$10,318
Repatha SureclickEvolocumab13$7,119
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$589$125,33899 claims
Lilly USA, LLCMounjaro$251$108,54686 claims
Boehringer IngelheimJardiance$554$104,73591 claims
AstraZenecaFarxiga, Brilinta$1,078$77,177114 claims
PfizerEliquis, Premarin$224$65,97886 claims
Johnson & JohnsonXarelto, Invokana$474$56,67454 claims
MerckJanuvia$220$52,66659 claims
AbbVieLinzess, Synthroid$1,537$46,33495 claims
NovartisEntresto$12$25,60727 claims
GSKTrelegy Ellipta$273$20,83629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →